Showing posts with label NSE. Show all posts
Showing posts with label NSE. Show all posts

Tuesday, January 12, 2016

Buy - Morepen Labs

Here is a small cap recommendation from Smart Investor 

Background :


Morepen Laboratories Limited is an India-based pharmaceutical company. The Company operates through four segments; they are Active Pharmaceutical Ingredients (API), Domestic Formulations, Diagnostics and Over the Counter (OTC). The API segment has developed new products like Sitagliptin Phosphate, Rosuvastatin Calcium, Olmesartan Medoxomil and Aliskiren in the Research and Development laboratory. 

The Domestic Formulations segment markets over 100 branded formulations in 8 major therapeutic segments. The Diagnostics segment markets under its own brand name Clinical and Home Health devices and Blood Banking machines. The OTC segment market brands like Burnol ,Lemolate, Sat-Isabgol, Option -72, Head-X, Fever-X , C- Candy and other Over the Counter (OTC) products. The Company has 3 manufacturing facilities, for manufacture of API, formulations and OTC products with international standings.

Source : Reuters

Trend : 

Short term : Down
Medium term : Up
Long term : Up

Return ratios :

The stock has given a steady returns and created wealth to the investors

1 month =  25%
3 months = 200%
6 months = 300%
12 months = 360%

Recommendation :

There has been turn around in fortunes of this company and one can expect decent up move from here.  Buy around Rs.30 levels and hold for a target of Rs.60 holding period of 12 months

Raghav


Smart Investor

No.24 Pattamal Plaza
3rd Cross Kammanahalli
BANGALORE 560084

Mobile / Whatsapp -08105-737-966

intellinvestor@gmail.com
www.twitter.com/SmartInvestor

Wednesday, December 23, 2015

Buy Syngene

Company Background :

Syngene is one of the leading contract research organizations in the country offering a suite of integrated, end-to-end discovery and development services for novel molecular entities across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. The company offers services through flexible business models that are customised to client’s requirements. These range from a full-time equivalent to a fee-for-service model, or a combination thereof.

Syngene delivers its services through a combination of scientific talent, globally accredited systems and R&D infrastructure. At the end of FY15, its tangible fixed assets (gross block) were Rs 931 cr. the company’s laboratory and manufacturing facilities located in Bengaluru are spread over more than 9 lakh sq. ft.  As of May 31, 2015, the company had 2,122 scientists, including 258 Ph.Ds. and 1,665 scientists with a Master’s degree.

Recommendation :

Investors with long time horizon of holding for more than 12 months should consider adding this scrip to their portfolio.  Buy on a weak days around Rs.350 levels and hold for a target of Rs.525

Smart Investor

No.24 Pattamal Plaza
3rd Cross Kammanahalli
BANGALORE 560084

Mobile / Whatsapp -08105-737-966

intellinvestor@gmail.com
www.twitter.com/SmartInvestor

Wednesday, March 12, 2014

HCL Info - What Next ??

The stock has risen more than 60% during the last 3 months.  On Dec 11 the scrip was hovering around Rs.21 levels and the run up to Rs.36 was pretty fast and furious.  While the Nifty rose just 3.23%   during last 3 months, BSE Sensex as well as BSE 50 rose 3.3%    during the same period, this scrip vaulted giving astounding returns to the investors !

Company Back ground :

HCL Infosystems Limited is an information and communication technology (ICT) company. It is engaged in developing and implementing ICT solutions for diverse market segments. It operates in three segments: computer systems and other related products and services, telecommunication and office automation, and Internet and related services. 

The computer systems and other related products and services consists of manufacturing of computer hardware systems, providing comprehensive systems integration, roll out and infrastructure management solutions. This segment also provides information technology (IT) services, including maintenance, facility management and ICT training. On November 10, 2011, it sold its equity stake in HCL Infinet Ltd. Consequently, HCL Infinet Ltd has ceased to be subsidiary of the Company. In August 2012, the Company, through its subsidiary HCL Insys Pte. Ltd., bought the remaining 40% interest held by the NTS Group in HCL Infosystems MEA FZCo.

What Next ?

With the market entering bullish zone all the small and mid cap shares are seeing re-rating and scaling new highs each passing day.  HCL Info may stay subdued in the days to come, taking a pause to jump  higher and higher.  For the time being our Team suggests to adopt a Sell on Rise SOR strategy for playing safe in this volatile counter.

Smart Investor
Equity Research Division

Ravina Consulting
No.24 Pattamal Plaza
3rd Cross Kamannahalli
BANGALORE 560048

For Stock Advise + Ideas
mail to intellinvestor@gmail.com
Talk / SMS 08105737966

Visit - www.ingeniousinvestor.in
Follow us - www.twitter.com/smartinvestor


Sunday, January 26, 2014

Buy - Eros Media on declines

Investors with a short-term perspective can buy Eros International Media at current levels. The stock found support in the band between Rs 105 and Rs 115 in August 2013 after an intermediate-term downtrend. Subsequently, the stock changed direction and has been on a medium-term uptrend. Significant support at Rs 155 and 200-day moving average around this level provided base for the stock’s short-term corrective decline.

On Monday, the stock surged 8 per cent accompanied by above average volume, breaching its 21- and 50-day moving averages. The relative strength index on the daily chart has entered the bullish zone from the neutral region indicating positive momentum. Both daily and weekly price rate of change indicators are hovering in the positive territory implying buying interest. The short-term outlook is bullish. It can extend the uptrend to Rs 187 and then to Rs 191 in the coming trading sessions. Buy the stock while maintaining a stop-loss at Rs 176.
The stock is finding support around Rs.160 and facing stiff resistance beyond Rs.185 which gives a trading range of Rs.25 for the Smart Investor
Smart Investor
Equity Research Division


For Stock Advise + Ideas
intellinvestor@gmail.com
Talk / SMS 08105737966

Visit - www.ingeniousinvestor.in

Sunday, January 5, 2014

BSE Mid Caps - Buy on declines

Dear  Smart Investors,

We are giving  a list of Mid Cap shares that are likely to outperform the broader markets.  The strategy here should be to buy on declines and exit on getting 15 - 20% returns with a holding period of 4-6 weels.


The sharp increase in prices make these ripe for a minor correction this week.  Wait for the dips to enter into these shares.

Smart Investor
Equity Research Division

Ravina Consulting
No.24 Pattamal Plaza
3rd Cross, Kammanahallli
BANGALORE 560084

For Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966

Read - www.ingeniousinvestor.blogspot.com
Follow us - www.twitter.com/smartinvestor
http://www.google.com/profiles/intellinvestor

Sunday, March 17, 2013

Tata Global Beverages - Buy on Declines !


We recommend a Buy in the stock of Tata Global Beverages from a long-term horizon. It is apparent from the charts of the stock that after marking a new high at Rs 181 in mid-November 2012, the stock reversed direction. This reversal was triggered by negative divergence in weekly relative strength index and daily moving average convergence divergence indicator. Since then, the stock has been in a short-term downtrend.

Last week, the stock breached its 21- and 50-day moving averages decisively and has been hovering well below them. The stock fell by 3 per cent reinforcing bearish momentum in the previous week. On Wednesday, the stock appears to have breached its key support at around Rs 130 by declining more than one per cent. The daily RSI has entered the bearish zone from the neutral region and weekly RSI is declining in the neutral region. The daily MACD is sloping down, in line with the stock price and featuring in the negative territory implying downward momentum.

Our short-term outlook for the stock is bearish. We expect its decline to prolong and reach our price target of Rs 115 or Rs 124 in next 2 weeks .   After hitting a 52 week high of Rs.181 the stock has been declining which is now near to the 6 months low of 127.

Smart Investors  with long-term perspective can consider buying  the stock with stop-loss at Rs 100 levels.

Smart Investor
Equity Research Division

Ravina Consulting
No.24 Pattamal Plaza
3rd Cross, Kammanahallli
BANGALORE 560084

For Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966

Read - www.ingeniousinvestor.blogspot.com
Follow us - www.twitter.com/smartinvestor
http://www.google.com/profiles/intellinvestor

Saturday, December 8, 2012

PC Jewellers - IPO - Apply


Compared to the public issues of Tribhovandas Bhimji Zaveri (TBZ) and Tara Jewels, PC Jeweller’s initial public offering (IPO) is priced lower, at a PE of 9.7-10.5 times FY12 earnings (considering post-issue capital). But that is for a reason.


Though the promoters have more than two decades of experience in the jewellery business, the company is relatively new (compared to its nearest competitors, particularly TBZ) in the jewellery retailing business. Second, its operations are concentrated in the northern region, with Delhi NCR forming 57 per cent of domestic revenue in the first half of FY13. On the flip side, it has reported strong growth in the past, coupled with healthy margins. Growth rates should remain healthy and geographical concentration risk will ease, thanks to expansion. In this backdrop, investors can subscribe to the offer.


The company is engaged in manufacture, retail and export of jewellery, with five manufacturing facilities spread over 83,000 sq ft. Exports (on a wholesale basis to international distributors) formed 33 per cent of revenues in the year’s first half, but its share is expected to go down with a focus on domestic business.

By FY14-end, the company aims to have 50 owned-stores across India, from 30 stores in 23 cities and eight states currently, with addition of 20 stores (half in the western and southern; rest in north and east), which is to be funded through the IPO proceeds. Retail area would also jump 81 per cent from the current 164,000 sq ft. While the expansion should mitigate the geographical concentration risk, establishing a strong brand name (as in northern India) in the new regions might not be easy.

The company’s ‘Jewels for Less’ scheme (50,000 members) started just two years earlier, has seen good response and its policy of ‘full refund’ for jewellery returned within seven days of purchase are positives and should help on this front.

The company has reported rapid and profitable growth in a short span of time, which instils confidence. Says CRISIL in its IPO grading note, “The pace of expansion has been faster compared to other players with addition of 25,000 sq ft every year. The stores have been profitable from the first year of operations."

Apart from expansion, sales growth (CAGR of 70 per cent in FY09-12, highest among its competitors) is also aided due to a focus on wedding jewellery (80 per cent domestic revenues), the largest segment and relatively less affected by slowdown since it is an essential (planned) purchase.

The company’s strategy is to open large formats (average size per store of 5,500 sq ft). Of the 30 stores, 27 have an area of over 3,000 square feet each, which includes 11 showrooms of more than 5,000 sq ft each (four above 10,000 sq ft).

Says Balram Garg, managing director of the company, “The large format reinforces our positioning as trusted jewellery retailer, enabling us to attract a diverse customer base, offers a wide range of jewellery, ensures effective inventory management and provides benefits of scale."

Put together, these moves along with the increasing contribution of diamond jewellery (32 per cent of revenues in the first half from 18 per cent four years ago) have led to higher operating profit margin (OPM) than its peers. And there is further scope for margin improvement. Says Garg, “We are more focused on bottomline growth as it will help expand our network faster." Declining share of exports in total mix will also help. Buying gold on lease basis (against purchase) since inception has ensured less pressure on the balance sheet. All these have helped net profit grow at a faster pace.


Smart Investor 
Equity Research Division

Ravina Consulting
No.24 Pattamal Plaza
3rd Cross, Kammanahallli
BANGALORE 560084

For Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966

Read - www.ingeniousinvestor.blogspot.com
Follow us - www.twitter.com/smartinvestor
http://www.google.com/profiles/intellinvestor

Thursday, November 15, 2012

IVRCL - Buy


We recommend a buy in the stock of IVRCL from a shortterm perspective. The stock has strong support at Rs 37 and it bounced off this level in June this year.
The stock once again took support at this level towards the end of August and after hovering here for two weeks, it reversed higher on Friday. The stock is up 15 per cent in the last two sessions signallingthe onset of a short-term uptrend.
It has moved above its 21- as well as 50-day moving averages. Momentum indicators such as daily relative strength index have moved into the bullish region implying that the up-move can continue in the shortterm.
The stock can move up to Rs 46.7 and then Rs 48.2 in the near-term. Short-term investors can buy the stock with stop at Rs 35
Bought to you by
Smart Investor
Equity Research Division 
Ravina Consulting
Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084
For Free Stock Advise + Ideas
Talk / SMS 08105737966 
Follow us -


Monday, November 5, 2012

Buy - Sun Pharma Advanced


We recommend a buy in the stock of Sun Pharma Advanced Research Company from a long-term horizon. It is seen from the charts of the stock that it has a significant long-term support in the base band between Rs 75 and 87. In the past, the stock has consistently reversed upwards whenever it had tested the aforesaid support band. 
Similarly, the stock took support from this support level in mid-June this year and bounced up. Since then, the stock has been on a modest medium-term uptrend. The stock surged 10 per cent with good volume, emphatically breaching its moving average compressions (21-, 50- and 200-day moving averages) at Rs 79 and its immediate resistance around Rs 95 on Tuesday.
We observe that there is an increase in daily volume in the past two trading sessions. The daily relative strength index is featuring in the bullish zone and weekly RSI is on the brink of entering this zone from the neutral region. The daily moving average convergence divergence indicator has signalled buy and is about to enter positive terrain.
We are bullish on the stock from a short-term perspective. We expect its rally to prolong and reach our price target of Rs 110 in the months ahead. Traders with near-term perspective can buy the stock with stop-loss at Rs 90 levels.
Bought to you by
Smart Investor
Equity Research Division 
Ravina Consulting
Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084
For Free Stock Advise + Ideas
Talk / SMS 08105737966 
Follow us -

Sell Bharath Forge




We recommend a sell in the stock of Bharat Forge from a short-term perspective. It is apparent from the charts of the stock that following a medium-term downtrend from its May 2012 peak of Rs 347, the stock took support at around Rs 275 last month. This support level also coincides with the 61.8 per cent fibonacci retracement level of the stock's prior up move. After testing the support at Rs 275, the stock bounced up. 

The stock's reversal is backed by a positive divergence in daily relative strength index and daily price rate of change indicator. Moreover, the stock breached its immediate resistance as well as 21-day moving average at around Rs 290 by gaining almost 3 per cent on Saturday. Both daily and weekly relative strength indices are moving higher in the neutral region towards the bullish zone. The daily price rate of change indicator has entered the negative territory implying buying interest. The daily moving average convergence divergence indicator has signalled a sell. 

We are bearish on the stock from a short-term perspective. We expect the stock’s down move to continue and reach our price target of Rs 250 or Rs 225 in the November month. Traders can consider buying the stock around 250 while maintaining stop-loss at Rs 230 levels.

Bought to you by
Smart Investor
Equity Research Division 
Ravina Consulting
Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084
For Free Stock Advise + Ideas
sowmya@ravinaconsulting.comTalk / SMS 08105737966 
Follow us -

Monday, July 16, 2012

Bata India - Buy on declines



"Bata India Ltd. (BIL) focused on premium products and sacrificed volume, which grew by a mere 1.1% in CY11. It has started focusing again on volume and as a result, volume grew 14% in 1QCY12. As per the management, volume growth is expected to remain in double-digits in CY12. Strong volume growth along with higher realisation (due to better product mix) should result in revenue growing 20.0-25.0% as against our estimate of 19.7% in CY12E. Revenue has already grown by a robust 30.6% in 1QCY12. The management is confident of doubling its revenue in the next four-five years."

"BIL opened ~67 new outlets (including Hush Puppies stores) in 1QCY12. It set up ~25 more stores in 2QCY12 and new store addition has already touched ~92 in 1HCY12, which is expected to be ~150-170 by the end of CY12. Of the total 146 outlets opened in CY11, around 53% were opened in 2HCY11, which resulted in high inventory and lower revenue from these outlets in CY11. Currently, BIL is front-loading the setting up of new outlets and out of the total target of ~150-170 outlets planned in CY12, it has already opened ~92 outlets in 1HCY12. BIL has started bar-coding its products and currently 60-70% of its products are bar-coded. As a result, BIL would be able to report healthy revenue growth and also control its inventory in CY12. BIL plans to incur a capex of Rs1,000mn - ~Rs700mn in retail and ~Rs300mn in upgrading its manufacturing facility - in CY12E."

"Footin, owned by BSO (Bata Shoe Organization), is very popular in Thailand, Bangladesh etc, catering to college-going youth in the range of 15-25 years. BIL launched Footin in India in 1QCY12, with its USP being contemporary designs at an affordable price of Rs500-700/pair. In order to de-link Bata’s brand image, BIL is setting up exclusive Footin outlets of 1,000-1,500 sq ft. It has already opened nine Footin outlets till now in Delhi and Mumbai, where the response has been excellent. Currently, the exercise is more of a trial and if the response stays buoyant, BIL plans to aggressively open Footin outlets in the next two-three years. BIL is also very bullish on kids and women segments and is looking at launching new brands, either BSO-owned or strong in-licensed brands, in India."

Valuation

"We expect BIL, which trades at CY13E P/E of 22.3x and EV/EBITDA of 13.5x, to witness a further re-rating. On the back of strong revenue/net profit CAGR of 18.8%/31.2%, respectively, likely over CY11-13E, BIL would continue to trade at premium multiples. The stock is attractively priced, with a PEG ratio of 0.87x CY12E," says Nirmal Bang research report.

Recommendation  

Bata was quoting around 530 levels on Jan 2, 2012 and has so far given investors a decent 60% appreciation.  There is more steam left in the stock as we believe it is likely to cross Rs.1000/- levels.

Smart Investor
Equity Research Division

Ravina Consulting
No.24 Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084

For Free Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966

Sunday, January 29, 2012

Stides Arcolab - Buy on declines

Strides Arcolab, a Bangalore-headquartered pharma company has sold its subsidiary Ascent Pharmahealth at an enterprise value of AU$ 375 million (about Rs 1,968 crore) to Watson Pharmaceuticals. The company is currently going through a restructuring phase. 

Strides had acquired a majority stake (50.1 per cent) in Australia-based Ascent Pharmahealth in August 2008. According to the news agency Reuters, this acquisition was valued at the price of AU$ 65 million (about Rs 260 crore). The company later had increased its shareholding up to 60.3 per cent. 

Ascent is one of the leading generics company in Australia. This company also has nine subsidiaries in countries like New Zealand, Singapore, Hong Kong, Malaysia and Brunei.  Ascent brought about 33 per cent of the revenues of Strides in CY2010. Ascent has grown by a healthy five-year compounded annual growth rate (CAGR) of 30 per cent in the topline. For the year 2010 the company reported sales of AU$ 132.3 million (about Rs 550 crore) while its net profit remained AU$ 12 million (about Rs 50 crore).

Its EBITDA margins remained at about 13 per cent, lower than the EBITDA margins of Strides (22 per cent) in the same year. For the year 2010 the company showed a growth rate of 26 per cent in topline and 30 per cent in the bottomline. This high growth has mainly arisen due to the high growth rates in the Australian pharma market. 

The Australian government has proposed a cut of 23 per cent in the pharma product prices from April 2012. Though the company is leading player in the Australian generics market, we believe that this would impact the margins of Ascent. 

Looking at the value that Strides has got for selling Ascent, we believe it will have a good impact on its balance-sheet. Its total debt as of June 2011 half-yearly result was Rs 2,419.51 crore. The company paid Rs 90 crore as half-yearly interest expense which works out to be Rs 180 crore of annual interest payment in 2011. Its interest cover ratio as per the same statement works out to be 2.15 which has decreased from 2.97 in the same period last year. Its debt to equity ratio stood at 0.74 in June 2011. In our opinion company will use the amount received from the Ascent deal to pay the debt and bring these ratios down. 

The company recently has also said that it will mainly focus on the injectable and specialties segment in which it has recently received many USFDA approvals. As we see it, the company is in a very good shape to take the benefit of these approvals in the coming years. Strides’ specialties division, Agila, is also doing well. In 2010 its revenues rose by 84 per cent and contributed about 39 per cent to the topline and 32 per cent in the EBITDA. 

Our Recommendation :
With the good price received for Ascent and many new products in the pipeline we believe that this stock will be an attractive bet going ahead. Investors could start looking to accumulate the stock during the dips.


Investors should buy the scrip on all declines to Rs.400 levels and target for a Rs.600 with a holding period of 12-15 months.



Bought to you by


Ingenious Investor
Equity Research Division


Ravina Consulting
Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084


For Free Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966


Read - www.ingeniousinvestor.blogspot.com
Follow us - www.twitter.com/smartinvestor



Thursday, January 26, 2012

BSE / NSE Weekly Review 20 Jan 2012




High volatility is expected in a truncated week ahead as traders roll over positions in futures & options segment as the January F&O contracts expire on 25th January 2012. The stock markets will remain closed on 26th January 2012, on account of Republic Day.

The RBI is widely expected to keep its key lending rate viz. the repo rate steady at the Third Quarter Review of Monetary Policy, scheduled on 24th January 2012, as headline inflation remains high. Investors’ focus is on Q3 results as well. The Q3FY12 results are likely to be weak due to lower volume growth in a slowing economy, higher raw material costs and higher interest charges. The focus will be on guidance from  the company managements on outlook for the remaining part of the year and for the next year.

Some of the companies declaring their results in the next week include L&T, Maruti Suzuki India, Sterlite Industries, Idea Cellular, GAIL and Kotak Mahindra Bank on 23rd January. Lupin, Cairn India, Grasim and Biocon on 24th January. Bank of Baroda, Sesa Goa, Union Bank of India, Rural Electrification orporation, Indian Hotels and Tata Communications on 25th January. Blue Star, NHPC, BHEL, NTPC, Bank of India and Canara Bank on 27th January




Indian Markets 
Strong results from HDFC Bank, ITC, Bajaj Auto, Wipro, TCS, HCL Technologies and Hero MotoCorp, and sustained buying by foreign funds pushed key benchmark indices to their highest level in more than six weeks. The S&P CNX Nifty moved past the psychological 5,000 level. Firm global stocks underpinned sentiment. The market gained in four out of the five trading sessions during the week ended 20th January 2012. Foreign institutional investors (FIIs) bought shares worth Rs 4441.37 crore in eight trading sessions from 10 to 19 January 2012, as per provisional data from the stock exchanges.

The BSE Sensex rose 584.39 points or 3.62% to 16,739.01, its highest closing level since 7 December 2011. The S&P CNX Nifty gained 182.60 points or 3.75% to 5,048.60, its highest closing level since 7 December 2011. The BSE Mid-Cap index rose 1.75%


Strong results from HDFC Bank, ITC, Bajaj Auto, Wipro, TCS, HCL Technologies and Hero MotoCorp, and sustained buying by foreign funds pushed key benchmark indices to their highest level in more than six weeks. The 50-unit S&P CNX Nifty moved past the psychological 5,000 levels. Firm global stocks underpinned sentiment. The market gained in four out of the five trading sessions during the week ended Friday, 20th January 2012.

Gains in world stocks triggered by stronger-than-expected GDP growth in China, the world's second biggest economy, in the fourth quarter of 2011, strong Q2 December 2011 results from IT major HCL Technologies and data showing buying of Indian stocks by foreign funds over the past few days, triggered a rally on the domestic bourses.

Trading for the week began on a positive note. Key benchmark indices registered small gains to reach 5-1/2-week closing highs on Monday, 16 January 2012 as the headline inflation hit 2-year low. This reinforced expectations that the central bank could start cutting interest rates in the coming months to revive slowing economic growth. The BSE Sensex rose 3.62% to 16,739.01and The S&P CNX Nifty gained 3.75% to 5,048.60, its highest closing level since 7 December 2011. The BSE Mid-Cap index rose 1.75% and the BSE Small-Cap index gained 1.71%. Both these indices under performed the Sensex.

Realty: 
The BSE Realty index rose 7.97% to close at 1708 levels. Among the heavyweights, Unitech, DLF, Oberoi Realty and HDIL gained 11.9%, 8.8% 8.7% and 8.3% respectively. India's largest realty firm by net profit DLF rose 8.8%. The company is reportedly planning to sell a convention centre project in Delhi and its wind power business for about Rs 1800 crore early next fiscal to reduce debt.

Metals: 
The BSE Metals index rose 4.10% to close at 11198 levels. All the industry majors were gainers. Hindaclo, Jindal Steel, Tata Steel and Coal India rose 7.7%, 6.4%, 5.0%, and 0.1% respectively.Metal stocks rose as data showing China's manufacturing gauge remaining in contraction mode in January 2012, boosted case for monetary policy easing in the world's second largest economy. Tata Steel rose 5.0%. The company  secured a major contract from Siemens Wind Power to supply 25,000 tonnes of high-quality profiled steel plate for wind towers.

Oil & Gas:  
The BSE Oil & Gas index rose 6.4% to close at 8325 levels. Among the heavyweights, Reliance, ONGC and Cairn India gained 8.4%, 5.9%, and 2.8% respectively. Reliance Industries jumped 8.4%. The stock surged after company said its board will consider a proposal for buyback of equity shares along with Q3 December 2011 earnings on Friday, 20th  January 2012. The last buyback program by RIL was done in the year 2004. Then, the company could only deploy around 5% of its planned purchase as the stock price had zoomed quite high.

Capital Goods: 
The BSE Capital Goods index rose 5.49% to  close at 9807 levels. Among the heavyweights, L&T, Siemens, and Bhel gained 8.6%, 4.1% and 2.6% respectively. Capital goods stocks rose on bargain hunting after a steep decline last month. India's largest power equipment maker by sales BHEL gained 2.6%. The company unveils its Q3 results on 27th January 2012. Larsen and Toubro is likely to register a 10%  growth in sales from its automation business in the next financial year

Bankex: 
The BSE Bankex index rose 5.9% in the week to close at 10912 levels. All the large players, namely SBI, Axis Bank, ICICI Bank, and HDFC Bank were gainers, gaining 8.7%, 7.3%, 6.7% and 4.1% respectively. Interest rate sensitive banking stocks rose on expectations that the Reserve Bank of India will start cutting interest rates in the coming months to prop up slowing economy. HDFC reported 31.4% growth in net profit to Rs 1429.70 crore on 35.6% increase in total income to Rs 8622.64 crore in Q3 December 2011 over Q3 December 2010. Bank said its asset quality remains healthy. The bank's capital adequacy ratio (CAR) remained strong at 16.3% as on 31 December 2011, against he regulatory minimum of 9%


Bought to you by

Ingenious Investor
Equity Research Division

Ravina Consulting
Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084

For Free Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966

Read - www.ingeniousinvestor.blogspot.com
Follow us - www.twitter.com/smartinvestor

www.facebook.com/ingeniousinvestor

Sunday, October 9, 2011

Q2 Results will disappoint markets

India Inc is likely to post a muted earnings growth for the second quarter of this fiscal, largely due to fall in rupee value, rising interest costs, high inflationary pressures and a global economic slump. The analysts expect the rupee's sharp depreciation alone to impact the corporate earnings by an average of 3-5 per cent, on account of losses suffered due to their forex exposure such as overseas loans.

Besides, the global economic slowdown, as also headwinds in domestic macroeconomic scenario, might have a ripple effect on the companies' second-quarter financial results, they said. Investment banking and equity research major CLSA said in its Q2 earnings preview report that the sharp depreciation of rupee is likely to significantly impact the earnings of companies with unhedged foreign currency liabilities. "Overall earnings growth would be muted due to the one- time impact of rupee depreciation, estimated at 3 per cent of earnings," CLSA said.

Brokerage firm Religare Capital also said that the signs of economic slowdown were expected to be reflected in the Q2 results and the Sensex companies could report a profit growth of less than 9 per cent for the quarter. Religare Capital expects good Q2 figures in the IT, banking, FMCG, cement and pharma sectors, while companies in the real estate, telecom, power and metal space could post disappointing results. Excluding the oil companies, the Q2 earnings growth for the Sensex companies could fall to below 5 per cent, as per Religare Capital estimates.

CLSA has estimated an earnings growth of 7 per cent for the Sensex companies for the second quarter. Interestingly, the earnings growth of the Sensex companies before taking into account exceptional items such as forex losses is estimated at over 13 per cent as per CLSA. The earnings season for the second quarter of the current financial year will commence when IT bellwether Infosys would declare its result on October 12. The country's most valued firm RIL is scheduled to announce its results on October 15.

The Q2 results are likely to act as the next trigger for the stock market, where its benchmark Sensex index has dropped by about 14 per cent in the second quarter. CLSA said that the rising interest costs was likely to have affected the margins across the board, making funds costlier for the companies. It said that the full impact of higher interest costs would be visible from the second quarter onwards and could become a potential source of disappointments.

Making things worse for the corporates, inflation remains at high level despite softening commodity prices, and this has already led to the Reserve Bank hiking its key rates 12 times in the past 18 months to control the price rise. "While the RBI's hawkish policy has now started hurting business growth, inflation remains meaningful despite the recent softening in commodity prices. Early to say if margins are reverting and if the earnings cycle has bottomed out," Religare said.

As per CLSA, the depreciation in rupee value -- of 10 per cent against the US dollar and 15 per cent against the Japanese yen -- would be another dampener for Q2 results. CLSA said that companies like Lanco, Ranbaxy and Tata Power were likely to report loss on this account in Q2, while the numbers could also be impacted of firms like Bharti Airtel, PFC, Suzlon, L&T, Tata Motors, Tata steel, JSW steel and a host of IT companies.

Brokerage firm Unicon Financial further cautioned that issues like shortage of fuel and environmental clearances also remain a major concern for the power sector. "The power ancillary companies are expected to post robust earnings on the back of strong order book. However new order inflows for these companies remains slow," it said.

Prabhudas Lilladher:

``We expect consensus downgrade to continue in the current quarter. It is skeptical about double digit earnings growth of FY12 and anticipates consensus earnings cut of 3-5% in Jul-Sep 2011 for the current fiscal. Earnings for Nifty are likely to grow by 8.6% (vs Cons.: 11.7%) YoY for FY12, whereas for FY13 growth is expected to be 15.1% (vs Cons.: 16.1%) YoY. We expect PAT (FY12e) for Nifty to grow by 14.7% YoY, against consensus expectation of 19.6% YoY growth. Moreover, for FY13 we are maintaining the growth momentum stable at 14.1% YoY growth, versus deceleration in consensus momentum to 16.2% YoY growth. We are expecting growth contribution to come from BFSI, Technology, and FMCG for FY12 and FY13, however we expecting mid to high single digit growth in Auto, Metals, Telecom and Cement.

Revenue growth of NIFTY companies (excl. Oil & Gas) would show a sharp drop to 15.5% in Q2FY12 YoY from 21.5% in the preceding quarter. This would mark the lowest QoQ growth in last 18 months. PAT growth continues on a downward trajectory and expected to post an anaemic 6.8% growth YoY, the lowest in 18 months. For companies under our coverage, Revenue and PAT are expected to grow YoY by 21.9% and 10.8%, respectively and QoQ by 5.2% and 3.4%, respectively. EBITDA margin (ex-BFSI) is expected to decline by 149bps YoY and 45bps QoQ. Elevated raw material costs, slackening demand due to uncertainty in macro environment and high interest rates are expected to impact the margins of Corporate India.``

Motilal Oswal:

``2QFY12 earnings will be reported amidst an adverse macro backdrop. Interest rates are up further 50-75bp during the quarter, demand continued to weaken in domestic economy and India rupee depreciated by ~10% against the USD. Aggregate (ex RMs) Sales growth 20.9%, EBIDTA growth 11.7%, PAT growth 9.7%. EBIDTA margin will contract 190bp YoY to 23.6% (2nd lowest in last 8 years), PAT margin will contract 120bp YoY to 12.7% (lowest in last 8 years).

Number of companies with growth rates of over 30% is the lowest at 19%, while percentage of companies with YoY decline is at a 8 quarter high of 33%.

Top 3 contributors to aggregate earnings are Financials, Oil & Gas and Metals, accounting for 57% of the 2QFY12 earnings.

Sectors with strong YoY PAT growth include Cement (67% YoY due to low base effect), Private Banks (+23% YoY) and Oil & Gas (excl. RMs) 21% YoY. FMCG, Private Banks and Retailing are the only 3 sectors where all companies will report earnings growth. Sectors with disappointing / muted growth are PSU Banks, Telecom, Autos. Telecom with a decline of 44% shaves off 200bp from aggregate growth.``

ICICI Securities:

``The I-direct coverage universe (ex- BFSI) is expected to post a YoY revenue growth of 21.3% while QoQ growth would be modest at 2.1% since Q2 is a cyclically weak quarter for most sectors. At the same time, EBITDA growth of 7% YoY will not mirror the revenue growth as most of the companies under coverage will face the full blown impact of high input prices and rise in other operating expenditure. This, we believe, will impact operating margins by 215 bps to 16.1% in Q2FY12. Even though topline and operating profits will register positive growth rates, profitability will come under pressure due to the unabated hike in key policy rates by the RBI. Hence, we estimate an 11.4% YoY decline in net profit for our coverage universe for Q2FY12. This performance would be slightly better as PAT, excluding oil & gas, would decline 6.5% YoY. What will be highly crucial to determine during the quarter would be whether the earnings downgrade cycle gets intensified as we face significant local and macro headwinds? As of now, we expect the broader market earnings to grow at 11% CAGR over FY11-FY13E.``

Angel Broking:

``Margin pressures have dented the profitability of Indian corporates over the past few quarters and are likely to continue in 2QFY2012 as well. While top-line growth for Sensex companies is expected to remain healthy at 21.1% yoy (muted 2.6% qoq), margin pressures are likely to result in PAT growth falling to sub-10% (at 8.2%) level. However, on a sequential basis, both operating and net profit margins are expected to improve, albeit marginally. Earnings expected to grow at 7.4% yoy, driven by 18.6% yoy top-line growth.`
Bought to you by

Ingenious Investor
Equity Research Division

Ravina Consulting
Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084

For Free Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966

Read - www.ingeniousinvestor.blogspot.com
Follow us - www.twitter.com/smartinvestor
 

Tuesday, August 23, 2011

Ramky Infra - Sell

The stocks of Ramky Infra, took a severe battering in today’s trading, as all these Hyderabad-based entities are now under CBI scanner.

All are Hyderabad based listed entities now under CBI scanner.

These stocks in particular were apparently reacting to the recent investigations initiated by the CBI into companies owned or promoted by Mr Y.S. Jagan Mohan Reddy, Member of Parliament, and president of YSR Congress Party and son of late Chief Minister of Andhra Pradesh, Rajasekhara Reddy.

Following the Andhra Pradesh High Court directive, the CBI, is investigating into issues relating to transactions of corporates with which Mr Reddy and his firms, and the investments they had made to secure land to set up special economic zones, etc.

The shares of Ramky Infrastructure closed the day's trade at Rs 227.05 down Rs 42.95 against previous day's closing trade of Rs 270. The company's 52-week high and low was Rs. 460 and Rs 242.70 respectively

The scrip has been underperforming in line with the infrastructure space. The following information gives information the returns in the last 6 months.

Particular Week 1M 3M 6M



Price283.60283.50260.00295.05



Net Change-56.55-56.45-32.95-68.00



%Change-19.94-19.91-12.67-23.05

Our Recommendation :

We recommend investors to get out of the stock on any spike and long term investors can considering buying the share if it falls below its book value of Rs. 180 for a target price of 250 in next 6-9 months.

Bought to you by

Ingenious Investor
Equity Research Division

Ravina Consulting
Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084

For Free Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966

Read - www.ingeniousinvestor.blogspot.com
Follow us - www.twitter.com/smartinvestor

NB Ventures - Sell

Nava Bharat Ventures Ltd., which is into sugar, ferro alloys, power generating and lately ventured into mining, has also taken a beating with its shares closing the day's trade lower by Rs 17 to close at Rs 175.55 (previous close of Rs 192.55)

Time Span Price Change %Change
Today 175.55 -17.00 -8.82
Week 200.85 -8.30 -4.13
Month 219.55 -27.00 -12.29
Three Months 230.05 -37.50 -16.30
Six Months 256.00 -63.45 -24.78
One Year 363.85 -171.30 -47.07

Our recommendation :

With on going investigations by CBI the companys management will be under cloud and is likely to be a non performer in the short term. Long term investors can buy the scrip if it falls to 125 levels though.

Bought to you by

Ingenious Investor
Equity Research Division

Ravina Consulting
Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084

For Free Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966

Read - www.ingeniousinvestor.blogspot.com
Follow us - www.twitter.com/smartinvestor